<DOC>
	<DOCNO>NCT00354198</DOCNO>
	<brief_summary>We recently demonstrate pentoxifylline ( PTX ) potential treat severe glomerular inflammation rat model accelerate anti-glomerular basement membrane ( GBM ) glomerulonephritis . This study aim investigate therapeutic effect combine PTX conventional immunosuppressive regimen patient rapidly progressive glomerulonephritis .</brief_summary>
	<brief_title>Efficacy Pentoxifylline Rapidly Progressive Glomerulonephritis</brief_title>
	<detailed_description>Corticosteroids cytotoxic agent cyclophosphamide remain commonly use regimen crescentic glomerulonephritis . However , use often limited adverse effect , notably life-threatening opportunistic infection due generalize immunosuppression . Over past decade , number novel experimental therapeutic agent show ameliorate severity experimental crescentic glomerulonephritis . Unfortunately , none measure currently available clinical use . Other potential agent mycophenolate , cyclosporin , tacrolimus , clinically available , share similar adverse effect corticosteroid- cyclophosphamide-based regimen . PTX methylxanthine phosphodiesterase inhibitor widely use treat peripheral vascular disease cerebrovascular disorder . In addition well-known hemorheologic activity , accumulate evidence suggest PTX also possess potent anti-inflammatory and/or immunoregulatory activity . For example , PTX show efficacy different animal model renal disease tumor necrosis factor ( TNF ) -alpha , monocyte chemoattractant protein ( MCP ) -1 , intercellular adhesion molecule-1 involve . Moreover , clinical trial patient diabetic nephropathy membranous glomerulonephritis show PTX lower endogenous TNF-alpha attenuate proteinuria . These data raise possibility PTX may promise anti-inflammatory agent via ability antagonize inflammatory mediator . Consistent idea , demonstrate potential usefulness PTX rat model accelerate anti-GBM glomerulonephritis . More recently , report PTX capable inhibit proteinuria via renal MCP-1 production subnephrotic primary glomerular disease . In study , aim investigate potential benefit combine PTX conventional immunosuppressive regimen , compare conventional immunosuppressive therapy , patient rapidly progressive glomerulonephritis . This study randomize , open-label , comparative study . Group A treat three monthly standard intravenous pulse-dose methylprednisolone ( 15 mg/kg/day maximum 1 g/day day 1 3 ) follow oral prednisolone 0.5-1.0 mg/kg/day ( day 4-30 ) . Group B treat corticosteroid regimen plus intravenous PTX ( 0.33-0.66 mg/kg/h day 1 7 ) follow oral PTX 400-800 mg/day ( day 8-90 ) . The dose intravenous PTX determine estimate GFR , patient whose GFRs 30-59 ml/min/1.73 m2 give 0.66 mg/kg/h , 30 ml/min/1.73 m2 give 0.33 mg/kg/h . The oral dose PTX also determine estimate GFR . Patients whose estimate glomerular filtration rate ( GFRs ) 30-59 ml/min/1.73 m2 give 800 mg/day , 30 ml/min/1.73 m2 give 400 mg/day . If patient tolerate oral medication , either PTX corticosteroid administer intravenously patient resume oral intake . Serum single-voided urine specimen collect hospital initiation therapy ( day 0 ) , day 8 , 15 , 30 , 90 commencement therapy . Renal function calculate Cockcroft-Gault simplify Modification Diet Renal Disease formula . All biochemical immunological analysis perform Department Laboratory Medicine , National Taiwan University Hospital . Serum urine sample measure inflammatory mediator use commercial ELISA kit .</detailed_description>
	<mesh_term>Glomerulonephritis</mesh_term>
	<mesh_term>Pentoxifylline</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>biopsiedproved crescentic glomerulonephritis , rapidly progressive renal failure AntiGBM disease , Dialysisdependency pulmonary hemorrhage , History allergy pentoxifylline , Females nursing pregnant , Congestive heart failure , Unstable angina , myocardial infarction , coronary artery bypass graft surgery , percutaneous coronary intervention , within past 6 month prior sign inform consent form , Cerebral hemorrhage within past 6 month prior sign inform consent form , Retinal hemorrhage within past 6 month prior sign inform consent form , Known suspect secondary hypertension , Uncontrolled hypertension diabetes , Liver cirrhosis hepatic dysfunction define liver enzymes &gt; 2 time upper limit normal range , Biliary obstructive disorder , Active malignancy infection</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>rapidly progressive glomerulonephritis</keyword>
	<keyword>pentoxifylline</keyword>
</DOC>